ATH 25.0% 0.3¢ alterity therapeutics limited

Progress, page-33

  1. 5,922 Posts.
    lightbulb Created with Sketch. 151
    Considering Prana's stated intention of looking for other opportunities for lower dose or short use for PBT2, I think the work you did on those trial results ITM is very important. It puts those IMAGINE results into perspective.
    No doubt that trial size was a mistake, but it was the first ever imaging trial for an MPAC, AIBL data which was emerging suggested 40 patients could work and they were strapped for cash after the GFC of 2008.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.